---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-146410"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:37:39.859376+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Coherus Biosciences appoints Charles Newton to Board of Directors

## Summary
- Charles Newton appointed as Class I director effective May 4, 2022, term expiring at 2024 annual meeting.
- Newton also appointed to audit committee; is CFO of Lyell Immunopharma, a Nasdaq-listed biotech.
- He receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.
- Newton previously co-headed healthcare investment banking at BofA Securities and Credit Suisse.
- No material transactions requiring disclosure under Item 404(a) identified.

## SEC filing metadata
- accession: 0001193125-22-146410
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312522146410/0001193125-22-146410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312522146410/d328049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-146410
- JSON: https://secwatch.observer/filing/0001193125-22-146410.json
- Plain text: https://secwatch.observer/filing/0001193125-22-146410.txt

## Key facts
- Executive change
  Charles Newton was appointed as Class I director at Coherus Oncology, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On May 4, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), a vacancy on the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) was filled with the appointment of Charles Newton.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000119312522146410/0001193125-22-146410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.